uridine triacetate (BioDeep_00000743743)

   


代谢物信息卡片


uridine triacetate

化学式: C15H18N2O9 (370.1012258)
中文名称: 2,3,5-三乙酰尿苷
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
InChI: InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1

描述信息

A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products
C78275 - Agent Affecting Blood or Body Fluid
Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS)[1][2].

同义名列表

2 个代谢物同义名

uridine triacetate; Tri-O-acetyl uridine



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Amin Osman Elzupir. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment. Molecules (Basel, Switzerland). 2021 Dec; 26(24):. doi: 10.3390/molecules26247458. [PMID: 34946540]
  • NULL. In brief: Uridine triacetate (Xuriden) for hereditary orotic aciduria. The Medical letter on drugs and therapeutics. 2016 Mar; 58(1491):e49. doi: NULL. [PMID: 27027693]
  • Joel A Saydoff, Ana Olariu, Jin Sheng, Zhongyi Hu, Qin Li, Rolando Garcia, Jiong Pei, Grace Y Sun, Reid von Borstel. Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. Journal of Alzheimer's disease : JAD. 2013; 36(4):637-57. doi: 10.3233/jad-130059. [PMID: 23648515]
  • Melissa E Weinberg, Mark C Roman, Peyton Jacob, Michael Wen, Polly Cheung, Ulrich A Walker, Kathleen Mulligan, Morris Schambelan. Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PloS one. 2011 Feb; 6(2):e14709. doi: 10.1371/journal.pone.0014709. [PMID: 21379380]
  • Rolando A G Garcia, Liansheng Liu, Zhongyi Hu, Alexis Gonzalez, Reid W von Borstel, Joel A Saydoff. Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. Brain research. 2005 Dec; 1066(1-2):164-71. doi: 10.1016/j.brainres.2005.10.056. [PMID: 16330000]
  • O M Ashour, F N Naguib, R P Panzica, O N Al Safarjalani, M H el Kouni. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine. Biochemical pharmacology. 2000 Aug; 60(3):427-31. doi: 10.1016/s0006-2952(00)00342-7. [PMID: 10856438]
  • O M Ashour, F N Naguib, N M Goudgaon, R F Schinazi, M H el Kouni. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. Cancer chemotherapy and pharmacology. 2000; 46(3):235-40. doi: 10.1007/s002800000138. [PMID: 11021741]
  • M Hidalgo, M A Villalona-Calero, S G Eckhardt, R L Drengler, G Rodriguez, L A Hammond, S G Diab, G Weiss, A M Garner, E Campbell, K Davidson, A Louie, J D O'Neil, R von Borstel, D D Von Hoff, E K Rowinsky. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Jan; 18(1):167-77. doi: 10.1200/jco.2000.18.1.167. [PMID: 10623707]
  • D P Kelsen, D Martin, J O'Neil, G Schwartz, L Saltz, M T Sung, R von Borstel, J Bertino. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Apr; 15(4):1511-7. doi: 10.1200/jco.1997.15.4.1511. [PMID: 9193347]